FR2841904B1 - Analogues de facteurs x clivables par la thrombine - Google Patents

Analogues de facteurs x clivables par la thrombine

Info

Publication number
FR2841904B1
FR2841904B1 FR0208299A FR0208299A FR2841904B1 FR 2841904 B1 FR2841904 B1 FR 2841904B1 FR 0208299 A FR0208299 A FR 0208299A FR 0208299 A FR0208299 A FR 0208299A FR 2841904 B1 FR2841904 B1 FR 2841904B1
Authority
FR
France
Prior art keywords
thrombin
factor
clavable
factor analogs
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0208299A
Other languages
English (en)
Other versions
FR2841904A1 (fr
Inventor
Virginie Louvain
Elsa Bianchini
Pierre Emmanuel Marque
Tareau Claire Calmel
Martine Aiach
Bonniec Bernard Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0208299A priority Critical patent/FR2841904B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to AT03762681T priority patent/ATE316101T1/de
Priority to ES03762681T priority patent/ES2257693T3/es
Priority to PCT/EP2003/007793 priority patent/WO2004005347A1/fr
Priority to AU2003250095A priority patent/AU2003250095B2/en
Priority to EP03762681A priority patent/EP1539816B1/fr
Priority to DE60303312T priority patent/DE60303312T2/de
Priority to CA2491040A priority patent/CA2491040C/fr
Priority to JP2004518770A priority patent/JP4533137B2/ja
Priority to US10/518,390 priority patent/US8168753B2/en
Publication of FR2841904A1 publication Critical patent/FR2841904A1/fr
Application granted granted Critical
Publication of FR2841904B1 publication Critical patent/FR2841904B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FR0208299A 2002-07-03 2002-07-03 Analogues de facteurs x clivables par la thrombine Expired - Fee Related FR2841904B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0208299A FR2841904B1 (fr) 2002-07-03 2002-07-03 Analogues de facteurs x clivables par la thrombine
JP2004518770A JP4533137B2 (ja) 2002-07-03 2003-06-30 トロンビン切断可能な第ｘ因子アナログ
PCT/EP2003/007793 WO2004005347A1 (fr) 2002-07-03 2003-06-30 Analogues du facteur x a clivage par la thrombine
AU2003250095A AU2003250095B2 (en) 2002-07-03 2003-06-30 Thrombin-cleavable factor X analogues
EP03762681A EP1539816B1 (fr) 2002-07-03 2003-06-30 Analogues du facteur x a clivage par la thrombine
DE60303312T DE60303312T2 (de) 2002-07-03 2003-06-30 Thrombin-spaltbare faktor x-derivate
AT03762681T ATE316101T1 (de) 2002-07-03 2003-06-30 Thrombinspaltbare faktor-x-analoga
ES03762681T ES2257693T3 (es) 2002-07-03 2003-06-30 Analogos de factor x escindibles por trombina.
US10/518,390 US8168753B2 (en) 2002-07-03 2003-06-30 Thrombin cleavable factor X analogues
CA2491040A CA2491040C (fr) 2002-07-03 2003-06-30 Analogues du facteur x a clivage par la thrombine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0208299A FR2841904B1 (fr) 2002-07-03 2002-07-03 Analogues de facteurs x clivables par la thrombine

Publications (2)

Publication Number Publication Date
FR2841904A1 FR2841904A1 (fr) 2004-01-09
FR2841904B1 true FR2841904B1 (fr) 2004-08-20

Family

ID=29725108

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0208299A Expired - Fee Related FR2841904B1 (fr) 2002-07-03 2002-07-03 Analogues de facteurs x clivables par la thrombine

Country Status (10)

Country Link
US (1) US8168753B2 (fr)
EP (1) EP1539816B1 (fr)
JP (1) JP4533137B2 (fr)
AT (1) ATE316101T1 (fr)
AU (1) AU2003250095B2 (fr)
CA (1) CA2491040C (fr)
DE (1) DE60303312T2 (fr)
ES (1) ES2257693T3 (fr)
FR (1) FR2841904B1 (fr)
WO (1) WO2004005347A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
EP1728798A1 (fr) * 2005-06-01 2006-12-06 ZLB Behring GmbH Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
EP1820508A1 (fr) 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
CA2850603C (fr) 2011-09-30 2021-11-16 The Children's Hospital Of Philadelphia Compositions et procedes pour moduler l'homeostasie
EP2858659B1 (fr) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Composés pro-coagulants
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
AU2014210830A1 (en) 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
JP2016510984A (ja) * 2013-03-12 2016-04-14 ノヴォ ノルディスク アー／エス トロンビン感受性凝固第ｘ因子分子
WO2015044836A1 (fr) 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprenant des populations hétérogènes de protéines de facteur xa de coagulation humain de recombinaison
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS634615A (ja) * 1986-06-25 1988-01-09 Hitachi Tokyo Electron Co Ltd 半導体装置製造装置
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
US5746875A (en) * 1994-09-16 1998-05-05 Applied Materials, Inc. Gas injection slit nozzle for a plasma process reactor
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
WO1998019965A1 (fr) * 1996-11-04 1998-05-14 Materials Modification, Inc. Synthese chimique par plasma hyperfrequence de poudres ultrafines
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
CH697092A5 (de) * 1998-12-24 2008-04-30 Sulzer Metco Ag Anordnung für eine Plasmaspritzanlage.

Also Published As

Publication number Publication date
AU2003250095A1 (en) 2004-01-23
EP1539816A1 (fr) 2005-06-15
DE60303312T2 (de) 2006-09-21
DE60303312D1 (de) 2006-04-06
WO2004005347A1 (fr) 2004-01-15
US8168753B2 (en) 2012-05-01
EP1539816B1 (fr) 2006-01-18
ATE316101T1 (de) 2006-02-15
FR2841904A1 (fr) 2004-01-09
US20060148038A1 (en) 2006-07-06
JP2006507806A (ja) 2006-03-09
CA2491040C (fr) 2012-05-01
CA2491040A1 (fr) 2004-01-15
ES2257693T3 (es) 2006-08-01
JP4533137B2 (ja) 2010-09-01
AU2003250095B2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
FR2841904B1 (fr) Analogues de facteurs x clivables par la thrombine
ATE549028T1 (de) Stabile analoga von glp-1
MX9300800A (es) Polimeros de beta-dicarbonilo y sistema para formar un cemento a partir de los mismos.
HUP0100652A1 (hu) X-Faktor analógok módosított proteáz hasítási hellyel
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
ATE446313T1 (de) Muteine von tränen-lipocalin
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
HUP0500634A2 (hu) Anyagok és eljárások az idegszövet helyreállításának elősegítésére
ES2190653T3 (es) Productos de reaccion del acido hialuronico y de aminoacidos naturales y su utilizacion en composiciones cosmeticas y farmaceuticas.
DK1682491T3 (da) Usymmetrisk geleringsmiddel
HK1075406A1 (en) Biologically stable liquid composition of fvIII, of vwf or of fviii/vwf complex of human origin
EP1641824A4 (fr) Analogues peptidiques de la superfamille des relaxines
DE60123232D1 (de) Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
ATE282607T1 (de) Tryptase-inhibitoren
ATE213937T1 (de) Spezielle halofantrinhaltige zusammensetzungen
NO20026147L (no) Trombomodulinanaloger for farmasoytisk anvendelse
DE60006558D1 (de) Stabile lösung von calcitriol zum verpacken in phiolen
DE69831257D1 (de) Histogranin peptide und deren analgetische verwendung
HK1091816A1 (en) Diphenylurea derivatives and their use as chloride channel blockers
DE50312414D1 (de) Kompositmaterialien aus calciumverbindungen und glucuronsäurehaltigen polysacchariden
PE20001364A1 (es) UTILIZACION DE ACEITES VEGETALES INSAPONIFICABLES PARA LA PREPARACION DE UN MEDICAMENTO QUE ESTIMULA LA EXPRESION DEL TGF-ß O LA EXPRESION DEL INHIBIDOR PAI-1 DEL ACTIVADOR DEL PLASMINOGENO

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080331